NASDAQ:QURE uniQure (QURE) Stock Price, News & Analysis $24.69 -0.24 (-0.96%) Closing price 04:00 PM EasternExtended Trading$24.65 -0.04 (-0.18%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About uniQure Stock (NASDAQ:QURE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get uniQure alerts:Sign Up Key Stats Today's Range$24.01▼$25.1650-Day Range$14.73▼$29.1752-Week Range$8.73▼$71.50Volume872,077 shsAverage Volume2.11 million shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$42.83Consensus RatingModerate Buy Company Overview uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market. Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease. The company leverages its scalable manufacturing capabilities and in-house process development teams to optimize vector production and ensure supply chain robustness. Through strategic partnerships and collaborations, uniQure also explores ex vivo approaches for oncology and the engineering of next-generation AAV capsids to broaden its therapeutic reach. Founded in 1998 as a spin-off from academic research in the Netherlands, uniQure has built a transatlantic presence with its corporate headquarters in Lexington, Massachusetts, and its European research and manufacturing operations in Amsterdam. This geographic footprint enables the company to engage with leading clinical centers and regulatory authorities across North America and Europe, while advancing global registration strategies for its therapies. The company’s leadership team is led by President and Chief Executive Officer Jeroen Louwerse, who brings extensive experience in gene and cell therapy development. Under his guidance, uniQure continues to invest in research and manufacturing infrastructure and to expand its scientific collaborations. The company remains committed to delivering durable, one-time treatments that have the potential to transform the standard of care for patients with serious genetic disorders.AI Generated. May Contain Errors. Read More uniQure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreQURE MarketRank™: uniQure scored higher than 67% of companies evaluated by MarketBeat, and ranked 258th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatinguniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on no strong buy ratings, 10 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialuniQure has a consensus price target of $42.83, representing about 73.5% upside from its current price of $24.69.Amount of Analyst CoverageuniQure has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about uniQure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for uniQure are expected to grow in the coming year, from ($3.68) to ($3.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of uniQure is -7.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of uniQure is -7.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatiouniQure has a P/B Ratio of 10.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about uniQure's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.96% of the float of uniQure has been sold short.Short Interest Ratio / Days to CoveruniQure has a short interest ratio ("days to cover") of 7.03.Change versus previous monthShort interest in uniQure has recently decreased by 2.82%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YielduniQure does not currently pay a dividend.Dividend GrowthuniQure does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.90 News SentimentuniQure has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for uniQure this week, compared to 14 articles on an average week.Search InterestOnly 21 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.MarketBeat Follows2 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,850,434.00 in company stock.Percentage Held by Insiders4.79% of the stock of uniQure is held by insiders.Percentage Held by Institutions78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about uniQure's insider trading history. Receive QURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QURE Stock News HeadlinesuniQure (NASDAQ:QURE) Insider Walid Abi-Saab Sells 45,000 SharesMay 13, 2026 | insidertrades.comUniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In PlayMay 12, 2026 | seekingalpha.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 19 at 1:00 AM | American Alternative (Ad)uniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportMay 8, 2026 | finance.yahoo.comUniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 7, 2026 | msn.comUniQure plans U.K. AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029May 5, 2026 | seekingalpha.comuniQure N.V. (QURE) Q1 2026 Earnings Call TranscriptMay 5, 2026 | seekingalpha.comUniQure: Q1 Earnings SnapshotMay 5, 2026 | chron.comSee More Headlines QURE Stock Analysis - Frequently Asked Questions How have QURE shares performed this year? uniQure's stock was trading at $23.93 at the beginning of the year. Since then, QURE shares have increased by 3.2% and is now trading at $24.69. How were uniQure's earnings last quarter? uniQure N.V. (NASDAQ:QURE) released its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The biotechnology company earned $3.56 million during the quarter, compared to analysts' expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative trailing twelve-month return on equity of 145.81%. Read the conference call transcript. When did uniQure IPO? uniQure (QURE) raised $76 million in an initial public offering (IPO) on Wednesday, February 5th 2014. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Who are uniQure's major shareholders? Top institutional shareholders of uniQure include Orbimed Advisors LLC (3.39%), Jennison Associates LLC (1.96%), Siren L.L.C. (1.59%) and SG Americas Securities LLC (1.24%). Insiders that own company stock include Matthew C Kapusta, Christian Klemt, Walid Abi-Saab, Ricardo Dolmetsch, Jeannette Potts, Pierre Caloz, Madhavan Balachandran, Jeremy P Springhorn, David D Meek, Robert Gut, Leonard E Post, Rachelle Suzanne Jacques and Jack Kaye. View institutional ownership trends. How do I buy shares of uniQure? Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of uniQure own? Based on aggregate information from My MarketBeat watchlists, some other companies that uniQure investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/05/2026Today5/19/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 QURE's financial health is in the Green zone, according to TradeSmith. QURE has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QURE CIK1590560 Webwww.uniqure.com Phone(120) 240-6000Fax31-20-566-9272Employees500Year Founded1868Price Target and Rating Average Price Target for uniQure$42.83 High Price Target$95.00 Low Price Target$9.00 Potential Upside/Downside+73.5%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.97 million Net Margins-1,154.42% Pretax Margin-1,123.34% Return on Equity-145.81% Return on Assets-27.15% Debt Debt-to-Equity Ratio0.33 Current Ratio10.40 Quick Ratio10.40 Sales & Book Value Annual Sales$16.10 million Price / Sales96.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book10.42Miscellaneous Outstanding Shares63,070,000Free Float60,045,000Market Cap$1.56 billion OptionableOptionable Beta0.87 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:QURE) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding uniQure N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share uniQure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
